Opiate agents;Agentes opioides

Revista de la Sociedad Espanola del Dolor

Volumn 13, Issue SUPPL. 1, 2006, Pages 13-33

  Álamo González, Cecilio ^a   López Muñoz, Francisco ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Analgesic opiates; Endogenous opioid system; Heroin; History of medicine; Morphine; Opioid receptors; Opium; Pain

Indexed keywords

ANALGESIC AGENT; CODEINE; DIAMORPHINE; DRESER; FENTANYL; LEVORPHANOL; METHADONE; MORPHINE; OPIATE; OPIATE RECEPTOR; OXYCODONE; PEPTIDE; PETHIDINE; TRAMADOL; UNCLASSIFIED DRUG;

DRUG MIXTURE; DRUG SYNTHESIS; ELIXIR; HISTORY OF MEDICINE; HUMAN; PAIN; REVIEW;

EID: 33749659029     PISSN: 11348046     EISSN: 11348046     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Sneader W. Drug discovery: the evolution of modern medicines. Chichester, John Wiley & Sons, 1985.
2. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA, 1993; 90:5391-5393.
3. Murillo García H. Historia del tratamiento del dolor. En Torres LM, dir. Medicina del dolor. Barcelona, Masson, S.A., 1997; pp. 7-17.
4. Macht DI. The history of opium and some of its preparation and alkaloids. JAMA, 1915; 64:477-481.
5. Berridge V, Edwards G. Opium and the people. Opium use in Nineteenth-Century England. New Haven, Yale University Press, 1987.
6. Scott JM. The white poppy. A history of opium. New York, Funk and Wagnalls, 1969.
7. Stannard J. Hippocratic pharmacology. Bull Hist Med, 1961; 35:497-518.
8. Escohotado A. Historia de las drogas. Madrid, Alianza Editorial, 1989.
9. Latimer D, Goldberg J. Flowers in the blood. New York, Franklin Watts, 1981.
10. Bergman NA. The genesis of surgical anesthesia. Park Ridge, Wood Library-Museum of Anesthesiology, 1998.
11. Karch SB. The pathology of drug abuse. Boca Ratón, CRC Press, 1996.
12. Montiel L. La medicina de la mente en el período moderno. En López-Muñoz F, Álamo C, eds. Historia de la neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del sistema nervioso central. Madrid, Ediciones Eurobook S.L. y Servicio de Publicaciones de la Universidad de Alcalá, 1998; pp. 39-50.
13. López-Muñoz F, Álamo C. La fisiología del dolor en la obra de René Descartes. Rev Soc Esp Dolor, 1997; 4: 325-333.
14. Descartes R. El Tratado del Hombre (Quintas G, traducción y comentarios). Madrid, Alianza Editorial S.A., 1990.
15. Shampo MA, Kyle RA. René Descartes. JAMA, 1975; 232:1247.
16. Descartes R. Discurso del Método. Otros tratados. (Gual Mir A, traducción e introducción). Madrid, EDAF Ediciones-Distribuciones S.A., 1980; pp. 107-260.
17. th edition. New York, MacMillan, 1985; p. 491.
18. López Piñero JM. La iatroquímica de la segunda mitad del siglo XVII. En Historia Universal de la Medicina, tomo IV: Medicina Moderna. Barcelona, Salvat Editores S.A., 1973; pp. 279-296.
19. Laín Entralgo P. Historia de la Medicina. Barcelona, Salvat Editores S.A., 1978; pp. 245-253.
20. th centuries. From concept to experiment. Nueva York, Raven Press, 1984; pp. 18-28.
21. Shorter E. A history of psychiatry. From the era of the asylum to the age of Prozac. New York, John Wiley & Sons Inc, 1997.
22. Rey R. History of Pain. París, Editions La Découverte, 1993.
23. Schmitz R. Friedrich Wilhelm Sertürner and the discovery of morphine. Pharm Hist, 1985; 27:61-74.
24. Sertürner F. Auszage aus Briefen an den Herausgeber. (a) Säure im Opium, (b) Ein anderes Schreiben von Ebendenselben. Nachtrag zur Charakteristik der Säure im Opium. J Pharm f Arzte Apotheker u Chemisten von D.J.B. Trommsdorff, 1805; 13:56-89.
25. Sertürner FW. A Üeber das Morphium, ein neue salzfahige Grundlage, und die Mekonsäure, als Hauptbestandtheile des Opiums. Gilbert's Ann d Physik (Leipzig) 1817; 25:56-89.
26. Gregory W. On a process of preparing economically the muriate of morphia. Edin Med Surg J, 1831; 35: 331-338.
27. Rubio G, López-Trabada JR, Pascual J, Santo-Domingo J. Utilización de las drogas de abuso en el tratamiento de las enfermedades mentales. En López-Muñoz F, Álamo C, eds. Historia de la neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del sistema nervioso central. Madrid, Ediciones Eurobook S.L. y Servicio de Publicaciones de la Universidad de Alcalá, 1998; pp. 325-334.
28. Howard-Jones N. A critical study of the origins and early development of hypodermic medication. J Hist Med Allied Sci, 1947; 2:201-245.
29. Brau JL. Historia de las drogas. Barcelona, Editorial Bruguera, 1973.
30. Von Frey M. Beitrage zur Phisyologie des Schmerzsinnes. Ber Verhald zonig sach Ges Wiss Leipzig, 1894; 46:185-196, 288-296.
31. Goldscheider A. Ueber den Schmerz in Physiologischer und Klinischer Hinsicht. Berlín, Hirschwald, 1894.
32. Wright CRA. On the action of organic acids and their anhydrides on the natural alkaloids. Part I. J Chem Soc, 1874; 12:1031-1043.
33. Dott DB, Stockman R. The chemistry and pharmacology of some of the morphine derivatives. Year Book Pharmacy, 1887; pp. 538-548.
34. Dreser H. Pharmakologisches über einige Morphinderivate. Deut Med Wochenschr, 1898; 24:185-186.
35. Meldrum ML. A capsule history of pain management. JAMA 2003; 290:2470-2475.
36. Gulland JM, Robinson R. The morphine group. Part 1. A discussion of the constitution problem. J Chem Soc 1923; 123:980-998.
37. Grewe R. Synthetic drugs with morphine action. Angew Chem, 1947; 59:194-199.
38. Eisleb O, Schaumann O. Dolatin, ein neuartiges Spasmolytikum und Analgetikum. Dtsch Med Wochenschr, 1939; 65:967-968.
39. Schaumann O. A new class of compounds with spasmolytic and central analgesic action derived from 1-methyl-4-phenylpiperidine-4-carboxylic acid. Arch Exp Path Pharm, 1940; 196:109-136.
40. Eddy N. A new morphine-like analgesic. J Am Pharm Assoc, 1947; 8:536-540.
41. Maldonado R, Valverde O. Analgésicos opiáceos. En López-Muñoz F, Alamo C, eds. Historia de la neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del sistema nervioso central. Madrid, Ediciones Eurobook S.L. y Servicio de Publicaciones de la Universidad de Alcalá, 1998; pp. 419-430.
42. Janssen PA. A new series of potent analgesics. J Am Chem Soc, 1956; 78:3862.
43. Janssen PA, Jageneau AH, Demoen PJ, et al. Compounds related to pethidine-I. Mannich based derived from norpethidine and acetophenones. J Med Pharm Chem, 1959; 1:105-120.
44. Janssen PA, Jageneau AH, Demoen PJ, et al. Compounds related to pethidine-I. Mannich based derived from various esters of 4-carboxy-4- phenylpiperidine and acetophenones. J Med Pharm Chem, 1959; 1:309-317.
45. Janssen PA. A review of the chemical features associated with strong morphine-like activity. Br J Anaesth. 1962; 34:260-268.
46. Janssen PA, Niemegeers CJ, Dony JG. The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rat. Arzneimittelforsch, 1963; 13:502-507.
47. Weijlard J, Erickson AE. N-Allylnormorphine. J Am Chem Soc, 1942; 64:869-870.
48. Pohl J. Ueber das N-Allylnorcodein, einen Antagonisten des Morphins. Z Exper Pathol Ther. 1915; 18:370-382.
49. Lasagna L, Beecher HK. Analgesic effectiveness of nalorphine and nalorphine combinations in man. J Pharmacol Exp Ther, 1954; 112:356-363.
50. Maxwell RA, Eckhardt SB. Drug Discovery. A Case-book and Analysis. Clifton, Humana Press, 1990.
51. Archer S, Alberts NF, Harris LS, et al. Pentazocine. Strong analgesics and analgesic antagonist in the benzomorphan serie. J Med Chem, 1964; 7:123-127.
52. Martin WR, Eades CG. Pharmacological studies of spinal cord adrenergic and cholinergic mechanisms and their relation to physical dependence on morphine. Psychopharmacologia, 1967; 11:195-223.
53. Martin WR. Pharmacology of opioids. Pharmacol Rev, 1984; 35:283-323.
54. Reynolds DV. Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science, 1969; 164:444-445.
55. Goldstein A, Lowney LI, Pal BK. Stereospecific and non stereospecific interactions of the morphine congener levorphanol in sub cellular fractions of mouse brain. Proc Nat Acad Science USA, 1971; 68:1742-1747.
56. Simon EJ. Opiate receptors and endorphins: Possible relevance to narcotic addiction. Alcohol Subst Abuse, 1981; 1:13-31.
57. Snyder SH, Pasternak GW. Historical review: Opioid receptors. Trends Pharmacol Sci, 2003; 24:198-205.
58. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science, 1973; 179:1011-1014.
59. 3H-etorphine to rat brain homogenate. Proc Natl Acad Sci USA, 1973; 70:1947-1949.
60. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat brain cortex. Acta Pharmacol Toxicol (Copenh), 1973; 32:317-320.
61. Martin WR, Eades CG, Thompson J, et al. The effects of morphine and nalorphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther, 1976; 197:517-532.
62. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature, 1977; 267:495-499.
63. Schulz R, Fease E, Wuster M, Herz A. selective receptors for β-endorphin on the rat vas deferens. Life Sci, 1979; 24:843-850.
64. Oka T. Enkephalin receptor in the rabbit ileum. Life Sci, 1980; 38:1889-1898.
65. Grevel J, Sadee W. An opiate binding site in the rat brain is highly selective for 4,5-epoxymorphinans. Science, 1983; 221:1198-1200.
66. Zagon I, Goodman S, McLaughlin P. Characterization of zeta: A new opioid receptor involved in growth. Brain Res, 1989; 482:297-305.
67. Akil H, Mayer DJ, Liebeskind JC. Antagonism of stimulation-produced analgesia by naloxone, a narcotic antagonist. Science, 1976; 191:961-962.
68. Li CH. Lipotropin: A new active peptide from pituitary glands. Nature, 1964; 201:924.
69. Hughes J. Isolation of an endogenous compound from the brain with properties similar to morphine. Brain Res, 1975; 88:295-308.
70. Hughes J, Smith TW, Kosterlitz HW. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature, 1975; 258:577-580.
71. Li CH, Chung D. Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary gland. Proc Natl Acad Sci USA, 1976; 73:1145-1148.
72. Goldstein A, Tachibana S, Lowney LI, et al. Dynorphin-(1-13), an extraordinary potent opioid peptide. Proc Nat Acad Sci USA, 1979; 76:6666-6670.
73. Hokfelt T, Ljungdahl A, Terenius L, et al. The distribution of enkephalin-immunoreactive cell bodies in the rat nervous system. Neurosci Lett, 1977; 5:25-31.
74. Watson SJ, Akil H, Richard CW, Barchas JD. Evidence fo two separate opiate peptide neuronal systems. Nature, 1978; 275:226-228.
75. Evans CJ, Keith DE, Morrison H, et al. Cloning of a delta opioid receptor by functional expression. Science, 1992; 258:1952-1955.
76. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA, 1992; 89:12048-12052.
77. Chen Y, Mestek A, Liu J, et al. Molecular cloning and functional expression of a μ-opioid receptor from rat brain Mol Pharmacol, 1993; 44:8-12.
78. Fukuda K, Kato S, Mori K, et al. Primary structures and expression from cDNAs of rat opioid receptor δ- and μ-subtypes. FEBS Lett, 1993; 327:311-314.
79. Wang JB, Imai Y, Eppler CM, et al. μ Opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA, 1993; 90:10230-10234.
80. Li S, Zhu J, Chen C, et al. Molecular cloning and expression of a rat κ opioid receptor. Biochem J, 1993; 295:629-633.
81. Meng F, Xie GX, Thompson RC, et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci USA, 1993; 90:9954-9958.
82. Yasuda K, Raynor K, Kong H. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA, 1993; 90:6736-6740.
83. a edition. Boston, Little Brown, 1990.